Anxiolytic/NonsedatiVe Agents among Indol-3-ylglyoxylamides
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 12 3733
pyrimidines as Functionally Selective and Orally Bioavailable GABAA
R2/R3 Binding Site Agonists for the Treatment of Anxiety Disorders.
J. Med. Chem. 2006, 49, 35–38.
Visualization System for Exploratory Research and Analysis. J. Com-
put. Chem. 2004, 25, 1605–1612.
(43) Primofiore, G.; Da Settimo, F.; Marini, A. M.; Taliani, S.; La Motta,
C.; Simorini, F.; Novellino, E.; Greco, G.; Cosimelli, B.; Ehlardo,
M.; Sala, A.; Besnard, F.; Montali, M.; Martini, C. Refinement of the
Benzodiazepine Receptor Site Topology by Structure-Activity Re-
lationships of New N-(Heteroarylmethyl)indol-3-ylglyoxylamides.
J. Med. Chem. 2006, 49, 2489–2495.
(44) McKernan, R. M.; Rosahl, T. W.; Reynolds, D. S.; Sur, C.; Wafford,
K. A.; Atack, J. R.; Farrar, S.; Myers, J.; Cook, G.; Ferris, P.; Garrett,
L.; Bristow, L.; Marshall, G.; Macaulay, A.; Brown, N.; Howell, O.;
Moore, K. W.; Carling, R. W.; Street, L. J.; Castro, J. L.; Ragan, C. I.;
Dawson, G. R.; Whi, P. J. Sedative but not Anxiolytic Properties of
Benzodiazepines are Mediated by the GABAA Receptor R1 Subtype.
Nat. Neurosci. 2000, 3, 587–592.
(26) Da Settimo, A.; Primofiore, G.; Da Settimo, F.; Marini, A. M.;
Novellino, E.; Greco, G.; Martini, C.; Giannaccini, G.; Lucacchini,
A. Synthesis, Structure-Activity Relationships, and Molecular Model-
ing Studies of N-(Indol-3-ylglyoxylyl)benzylamine Derivatives Acting
at the Benzodiazepine Receptor. J. Med. Chem. 1996, 39, 5083–5091.
(27) Primofiore, G.; Da Settimo, F.; Taliani, S.; Marini, A. M.; Novellino,
E.; Greco, G.; Lavecchia, A.; Besnard, F.; Trincavelli, L.; Costa, B.;
Martini, C. Novel N-(Arylalkyl)indol-3-ylglyoxylylamides Targeted
as Ligands of the Benzodiazepine Receptor: Synthesis, Biological
Evaluation, and Molecular Modeling Analysis of the Structure-
Activity Relationships. J. Med. Chem. 2001, 44, 2286–2297.
(28) Da Settimo, A.; Primofiore, G.; Da Settimo, F.; Marini, A. M.;
Novellino, E.; Greco, G.; Gesi, M.; Martini, C.; Giannaccini, G.;
Lucacchini, A. N′-Phenylindol-3-ylglyoxylohydrazide Derivatives:
Synthesis, Structure-Activity Relationships, Molecular Modeling
Studies, and Pharmacological Action on Brain Benzodiazepine Recep-
tors. J. Med. Chem. 1998, 41, 3821–3830.
(45) Bourin, M.; Hascoe¨t, M. The Mouse Light/Dark Box Test. Eur.
J. Pharmacol. 2003, 463, 55–65.
(46) Hascoe¨t, M.; Bourin, M. A New Approach to the Light/Dark Test
Procedure in Mice. Pharmacol., Biochem. BehaV. 1998, 60, 645–
653.
(47) Costall, B.; Jones, B. J.; Kelly, M. E.; Naylor, R. J.; Tomlins, D. M.
Exploration of Mice in a Black and White Test Box: Validation as
a Model of Anxiety. Pharmacol., Biochem. BehaV. 1989, 32, 777–
785.
(48) Kilfoil, T.; Michel, A.; Montgomery, D.; Whiting, R. L. Effects of
Anxiolytic and Anxiogenic Drugs on Exploratory Activity in a
Simple Model of Anxiety in Mice. Neuropharmacology 1989, 28,
901–905.
(29) Primofiore, G.; Taliani, S.; Da Settimo, F.; Marini, A. M.; La Motta,
C.; Simorini, F.; Patrizi, M. P.; Sergianni, V.; Novellino, E.; Greco,
G.; Cosimelli, B.; Calderone, V.; Montali, M.; Besnard, F.; Martini,
C. Novel N-Substituted Indol-3-ylglyoxylamides Probing the LDi and
L1/L2 Lipophilic Regions of the Benzodiazepine Receptor Site in
Search for Subtype-Selective Ligands. J. Med. Chem. 2007, 50, 1627–
1634.
(30) Da Settimo, A.; Primofiore, G.; Marini, A. M.; Ferrarini, P. L.;
Franzone, J. S.; Cirillo, L.; Reboani, M. C. N-(Indol-3ylglyoxylyl) -
methionine Derivatives: Preparation and Gastric Antisecretory Activity.
Eur. J. Med. Chem. 1988, 23, 21–24.
(49) Young, R.; Johnson, D. N. A Fully Automated Light/Dark Apparatus
Useful for Comparing Anxiolytic Agents. Pharmacol., Biochem.
BehaV. 1991, 40, 739–743.
(31) Soerensen, U. S.; Teuber, L.; Peters, D.; Stroebaek, D.; Johansen, T. H.;
Nielsen, K. S.; Christophersen, P. Preparation of Novel 2-Aminoben-
zimidazole Derivatives as Modulators of Small-Conductance Calcium-
Activated Potassium Channels. PCT Int. Appl. WO 2006013210 A2,
2006.
(32) Borne, R. F.; Forrester, M. L.; Waters, I. W. Conformational Analogues
of Antihypertensive Agents Related to Guanethidine. J. Med. Chem.
1977, 20, 771–776.
(33) Gomtsyan, A.; Bayburt, E. K.; Lee, C.-H.; Koenig, J. R.; Schmidt,
R.; Lukin, K.; Chambournier, G.; Hsu, M.; Leanna, M. R.; Cink, R. D.
Preparation of Fused Heterocyclic Compounds as Vanilloid Receptor
Subtype 1 (VR1) Inhibitors. PCT Int. Appl. WO 2004111009 A1,
2004.
(34) Giannaccini, G.; Giacomelli, M.; Martini, C.; Lucacchini, A.; Piccolino,
M. Binding of the Benzodiazepine Ligand [3H]Ro 15-1788 to
Membrane Preparations of the Rabbit and Turtle Retina. Comp.
Biochem. Physiol., Part C: Toxicol. Pharmacol. 1992, 101, 337–342.
(35) Harris, R. A.; Proctor, W. R.; McQuilkin, S. J.; Klein, R. L.; Mascia,
M. P.; Whatley, V.; Whiting, P. J.; Dunwiddie, T. V. Ethanol Increases
GABAA Responses in Cells Stably Transfected with Receptor Subunits.
Alcohol.: Clin. Exp. Res. 1995, 19, 226–232.
(36) Street, L. J.; Sternfeld, F.; Jelley, R. A.; Reeve, A. J.; Carling, R. W.;
Moore, K. W.; McKernan, R. M.; Sohal, B.; Cook, S.; Pike, A.;
Dawson, G. R.; Bromidge, F. A.; Wafford, K. A.; Seabrook, G. R.;
Thompson, S. A.; Marshall, G.; Pillai, G. V.; Castro, J. L.; Atack,
J. R.; MacLeod, A. M. Synthesis and Biological Evaluation of
3-Heterocyclyl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-
a]phthalazines and Analogues as Subtype-Selective Inverse Agonists
for the GABAAR5 Benzodiazepine Binding Site. J. Med. Chem. 2004,
47, 3642–3657.
(50) Clayton, T.; Chen, J. L.; Ernst, M.; Richter, L.; Cromer, B. A.;
Morton, C. J.; Ng, H.; Kaczorowski, C. C.; Helmstetter, F. J.;
Furtmu¨ller, R.; Ecker, G.; Parker, M. W.; Sieghart, W.; Cook, J. M.
An Updated Unified Pharmacophore Model of the Benzodiazepine
Binding Site on γ-Aminobutyric Acida Receptors: Correlation with
Comparative Models. Curr. Med. Chem. 2007, 14, 2755–2775.
(51) Zhang, W.; Diaz-Arauzo, H.; Allen, M. S.; Koehler, K. F.; Cook, J. M.
Chemical and Computer Assisted Development of the Inclusive
Pharmacophore of Benzodiazepine Receptors. In Studies in Medicinal
Chemistry; ChoudharyM. I., Ed.; Harwood Academic Publishers:
Chichester, U.K., 1996; pp 303.
(52) Buhr, A.; Baur, R.; Malherbe, P.; Sigel, E. Point Mutations of the
R1ꢀ2γ2 γ-aminobutyric acidA Receptor Affecting Modulation of the
Channel by Ligands of the Benzodiazepine Binding Site. Mol.
Pharmacol. 1996, 49, 1080–1084.
(53) Sigel, E.; Baur, R.; Trube, G.; Mo¨hler, H.; Malherbe, P. The Effect
of Subunit Composition of Rat Brain GABAA Receptors on Channel
Function. Neuron 1990, 5, 703–711.
(54) Sawyer, G. W.; Chiara, D. C.; Olsen, R. W.; Cohen, J. B. Identification
of the Bovine γ-Aminobutyric Acid Type A Receptor R Subunit
Residues Photolabeled by the Imidazobenzodiazepine [3H]Ro15-4513.
J. Biol. Chem. 2002, 277, 50036–50045.
(55) Da Settimo, A.; Primofiore, G.; Da Settimo, F.; Marini, A. M.;
Novellino, E.; Greco, G.; Martini, C.; Senatore, G.; Lucacchini,
A. Synthesis of 3-(2′-Furoyl)indole Derivatives as Potential New
Ligands at the Benzodiazepine Receptor, Structurally More Re-
strained Analogues of Indoleglyoxylylamides. Farmaco 1995, 50,
311–320.
(56) Miller, R. B.; Frincke, J. M. Synthesis of Isoquinolines from Indenes.
J. Org. Chem. 1980, 45, 5312–5315.
(37) Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. A Semiempirical
Free Energy Force Field with Charge-Based Desolvation. J. Comput.
Chem. 2007, 28, 1145–1152.
(38) Cromer, B. A.; Morton, C. J.; Parker, M. W. Anxiety over GABA(A)
Receptor Structure Relieved by AChBP. Trends Biochem. Sci. 2002,
27, 280–287.
(39) Ernst, M.; Bruckner, S.; Boresch, S.; Sieghart, W. Comparative models
of GABAA Receptor Extracellular and Transmembrane Domains:
Important Insights in Pharmacology and Function. Mol. Pharmacol.
2005, 68, 1291–1300.
(40) Case, D. A.; Darden, T. E.; Cheatham, T. E. I.; Simmerling, C. L.;
Wang, J.; Duke, R. E.; Luo, R.; Merz, K. M., Wang, B.; Pearlman,
D. A.; Crowley, M.; Brozell, S.; Tsui, V.; Gohlke, H.; Mongan, J.;
Hornak, V.; Cui, G.; Beroza, P.; Schafmeister, C.; Caldwell, J. W.;
Ross, W. S.; Kollman, P. A. , AMBER 9; University of California:
San Francisco.
(57) Besnard, F.; Even, Y.; Itier, V.; Granger, P.; Partiseti, M.; Avenet,
P.; Depoortere, H.; Graham, D. Development of Stable Cell Lines
Expressing Different Subtypes of GABAA Receptors. J. Recept. Signal
Transduction Res. 1997, 17, 99–113.
(58) Martini, C.; Lucacchini, A.; Ronca, G.; Hrelia, S.; Rossi, C. A.
Isolation of Putative Benzodiazepine Receptors From Rat Brain
Membranes by Affinity Chromatography. J. Neurochem. 1982, 38,
15–19.
(59) Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein
Measurement With the Folin Phenol Reagent. J. Biol. Chem. 1951,
193, 265–275.
(60) Accelrys, Inc., San Diego, CA.
(61) Dauber-Osguthorpe, P.; Roberts, V. A.; Osguthorpe, D. J.; Wolff,
J.; Genest, M.; Hagler, A. T. Structure and energetics of ligand
binding to proteins. Proteins: Struct., Funct., Genet. 1988, 4, 31-
47.
(41) Sanner, M. F.; Python, A. Programming Language for Software
Integration and Development. J. Mol. Graphics Modell. 1999, 17, 57–
61.
(42) Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.;
Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF ChimerasA
(62) Fletcher, R. Unconstrained Optimization. In Practical Methods of
Optimization; John Wiley & Sons: New York, 1980; Vol. 1.
(63) Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A.
Development and Testing of a General Amber Force Field. J. Comput.
Chem. 2004, 25, 1157–1174.